Nabriva Therapeutics (Nasdaq: NBRV) reported positive results from a Phase 3 of lefamulin in patients with community-acquired bacterial pneumonia sending the stock price soaring $2.01 to close at $8.87.
Nabriva Therapeutics reports upbeat results
September 18, 2017 at 19:14 PM EDT
